ALNYLAM PHARMACEUTICALS, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on January 15, 2013, by Alnylam Pharmaceuticals, Inc. The filing discloses the entry into a material definitive agreement regarding an underwritten public offering of common stock.
Key Financial Metrics and Transaction Details
- Shares Offered: 8,000,000 shares of common stock.
- Public Offering Price: $20.13 per share.
- Price to Company: $18.9222 per share (after underwriting discounts).
- Expected Net Proceeds: Approximately $151.1 million (excluding over-allotment).
- Over-Allotment Option: Underwriters have a 30-day option to purchase up to an additional 1,200,000 shares.
- Expected Closing Date: January 22, 2013.
Note: This filing does not provide revenue, profit, cash flow, margin, or debt metrics for the company's operations.
Material Changes
The primary material change is the execution of an underwriting agreement with J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC. This transaction represents a significant capital raise intended to increase the company's liquidity. The shares are being issued pursuant to a shelf registration statement filed on December 21, 2012.
Outlook, Risks, and Management Commentary
The filing indicates the closing is subject to the satisfaction of customary closing conditions. No specific operational guidance, risk factors, or management commentary regarding future performance is included in this specific 8-K text, other than the confirmation of the capital raise.
Key Facts for Investor Verification
- Verify the final closing date of the offering (expected January 22, 2013).
- Confirm whether the underwriters exercise the 1,200,000 share over-allotment option.
- Review the attached press release (Exhibit 99.1) for details on the intended use of the $151.1 million in net proceeds.
- Check subsequent filings for the actual cash received and updated balance sheet liquidity.